S-1/A: Nuwellis Eyes $24 Million in Unit Offering to Bolster Working Capital

Nuwellis, Inc. plans to offer units and pre-funded units to raise capital for working capital and general corporate purposes.

Summary

• Nuwellis, Inc. is planning a public offering to sell up to 16,666,666 units, each consisting of one share of common stock, one Series A warrant, and one Series B warrant.
• The company is also offering pre-funded units to certain purchasers who would otherwise exceed beneficial ownership limits.
• The assumed combined public offering price is $0.48 per unit, based on the closing price of NUWE on February 2, 2024.
• The Series A warrants will have an exercise price equal to 100% of the public offering price per unit and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants, and will expire five years from the Initial Exercise Date.
• The Series B warrants will have an exercise price equal to 100% of the public offering price per unit and will be exercisable beginning on the Initial Exercise Date, and will expire 18 months from the Initial Exercise Date.
• The company intends to use the net proceeds for working capital and general corporate purposes.
• Lake Street Capital Markets and Maxim Group LLC are acting as placement agents for the offering, receiving a cash fee of 8.0% of the gross proceeds.
• One of Nuwellis' directors is the head of Life Science Investment Banking and a Managing Director of Lake Street, creating a conflict of interest.

Sentiment

Score: 5

Explanation: The announcement is neutral. It details a capital raise, which could be positive if successful, but also indicates potential dilution and Nasdaq compliance issues.

Positives

• The offering aims to strengthen the company's financial position.
• The capital raised will support working capital and general corporate purposes.
• The company has engaged placement agents to assist with the offering.

Negatives

• The offering may dilute existing shareholders' equity.
• The company's stock price is currently below $1.00, raising concerns about Nasdaq compliance.
• A conflict of interest exists due to a director's affiliation with Lake Street Capital Markets.
• There is no guarantee that the company will sell all of the offered securities.

Risks

• The offering may dilute existing shareholders' equity.
• The company's stock price is currently below $1.00, raising concerns about Nasdaq compliance.
• A conflict of interest exists due to a director's affiliation with Lake Street Capital Markets.
• There is no guarantee that the company will sell all of the offered securities.
• The company has broad discretion in the use of the net proceeds and may not use them effectively.
• The lack of an active market for the warrants may impair investors ability to sell their shares at the time they wish to sell them or at a price that they consider reasonable, may reduce the fair market value of their shares and may impair our ability to raise capital to continue to fund operations by selling shares and may impair our ability to acquire additional intellectual property assets by using our shares as consideration.

Future Outlook

The company intends to use the net proceeds of this offering for working capital and for general corporate purposes, including for continued investments in our commercialization efforts.

Industry Context

The medical device industry is competitive, and Nuwellis faces challenges in expanding market acceptance of its Aquadex System.

Stakeholder Impact

• Shareholders may experience dilution.
• The company's financial stability could be improved.
• The company's ability to invest in growth initiatives may be enhanced.

Next Steps

• The company will seek to complete the offering.
• The company will use the proceeds for working capital and general corporate purposes.
• The company will continue to monitor the closing bid price for the Companys common stock between now and June 4, 2024, and it will consider available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement.

Keywords

Nuwellis, units, warrants, offering, capital, common stock, pre-funded units, Series A warrants, Series B warrants